Daijiworld Media Network - New Delhi
New Delhi, Nov 20: The American Cancer Society (ACS) has issued updated guidelines recommending regular prostate cancer screening for men from the age of 50, citing a rise in advanced-stage prostate cancer cases.
The recommendations, published on November 12 in CA: A Cancer Journal for Clinicians, mark a shift from the organisation’s earlier emphasis on shared decision-making between patients and healthcare professionals.
Under the new guidelines, men at average risk are advised to undergo prostate-specific antigen (PSA) testing every two years between the ages of 50 and 69. Men at higher risk are advised to begin annual testing at the age of 45.

For men aged 70 to 74, the ACS recommends individualised decision-making. Those who choose screening should undergo a PSA test every two years until the age of 74.
The guidelines also state that men above 75 should not automatically be excluded from screening. Their PSA history, overall health and life expectancy should be considered while deciding whether testing is appropriate.
The ACS last updated its prostate cancer screening recommendations in 2010, when conflicting research findings raised concerns about whether the benefits of PSA testing outweighed its potential harms. However, longer-term studies have since provided stronger evidence supporting the benefits of early detection.
According to the ACS, prostate cancer diagnoses in the United States increased by around three per cent annually between 2014 and 2022. The rise, particularly in advanced-stage cases, has renewed attention on regular screening.
The updated recommendations draw partly on a 2025 follow-up study of the European Randomized Study of Screening for Prostate Cancer, which found that regular PSA screening was associated with a 13 per cent reduction in prostate cancer deaths over 23 years. Earlier research also indicated that screening could reduce the risk of metastatic prostate cancer.
Medical experts say early detection can help identify aggressive cancers before they spread. They also point out that prostate cancer evaluation has improved significantly, reducing the need for unnecessary biopsies.
In cases of elevated PSA levels, doctors may repeat the test within two weeks to three months to confirm the result. If levels remain high, further evaluation through prostate MRI or validated biomarker tests can help determine whether a biopsy is necessary.
The updated guidelines are expected to provide a more consistent approach to prostate cancer screening and encourage men to include PSA testing in routine health check-ups.